Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1701 - 1725 of 2344 in total
Selitrectinib is under investigation in clinical trial NCT03215511 (Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers).
Investigational
Matched Iupac: … 9-fluoro-15-methyl-2,11,16,20,21,24-hexaazapentacyclo[16.5.2.0^{2,6}.0^{7,12}.0^{21,25}]pentacosa-1(24
VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Investigational
SB-1578 is under investigation in clinical trial NCT01235871 (A Single and Multiple-Dose Study of SB1578).
Investigational
Matched Iupac: … 7,12,26-trioxa-19,21,24-triazatetracyclo[18.3.1.1^{2,5}.1^{14,18}]hexacosa-1(23),2,4,9,14,16,18(25),20(24
Formic acid (systematically called methanoic acid) is the simplest carboxylic acid. It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. It is commonly used as a preservative and antibacterial agent in livestock feed.
Experimental
Investigational
Matched Mixtures name: … Irospan 24/6 …
An essential amino acid that is required for the production of histamine.
Investigational
Nutraceutical
Matched Mixtures name: … AMINOSTERIL N-HEPA 8% ... Aminosteril Hepa 8 % - Infusionslösung ... AMINOSTERIL N-HEPA FOR INTRAVENOUS INFUSION 8% …
Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.
Nutraceutical
Matched Mixtures name: … AMINOSTERIL N-HEPA 8% ... Aminosteril Hepa 8 % - Infusionslösung ... AMINOSTERIL N-HEPA FOR INTRAVENOUS INFUSION 8% …
Experimental
Matched Iupac: … (1R,3R,5S)-8-[(4-butoxyphenyl)methyl]-3-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-8-methyl-8-azabicyclo ... [3.2.1]octan-8-ium …
Latrunculin A is an actin binding macrolide purified from the red sea sponge Latrunculia magnifica. It is under investigation for the treatment of cancer. It disrupts actin polymerization, prevents mitotic spindle formation and thus cell replication.
Experimental
Investigational
Propacetamol is a non-opioid analgesic devoid of the major contraindications. It is a derivative of acetaminophen, or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. Propacetamol is a parenteral formulation of paracetamol and thus, it is a prodrug that is completely hydrolyzed to paracetamol. It is not available in...
Experimental
Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
Investigational
Batefenterol has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.
Investigational
Matched Iupac: … 1-(2-{[2-chloro-4-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-5 …
Experimental
Liafensine is under investigation in clinical trial NCT00892840 (Multiple-Ascending Dose Study).
Investigational
Amlitelimab is under investigation in clinical trial NCT06181435 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)).
Investigational
Experimental
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which...
Investigational
Matched Description: … of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24
Experimental
Investigational
Displaying drugs 1701 - 1725 of 2344 in total